GBA1 and Parkinson disease: A single-center, open-label noncontrolled clinical trial with GBA-PD and iPD patients (ClinicalTrials.gov Identifier NCT02941822) shows that ambroxol achieves good cerebrospinal fluid penetration and improves motor symptom scores [103].